Lixivaptan + Placebo

Phase 3Terminated

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Autosomal Dominant Polycystic Kidney

Conditions

Autosomal Dominant Polycystic Kidney, ADPKD

Trial Timeline

Oct 28, 2021 → Aug 3, 2022

NCT ID

NCT04064346

About Lixivaptan + Placebo

Lixivaptan + Placebo is a phase 3 stage product being developed by Centessa Pharmaceuticals for Autosomal Dominant Polycystic Kidney. The current trial status is terminated. This product is registered under clinical trial identifier NCT04064346. Target conditions include Autosomal Dominant Polycystic Kidney, ADPKD.

What happened to similar drugs?

1 of 4 similar drugs in Autosomal Dominant Polycystic Kidney were approved

Approved (1) Terminated (1) Active (2)

✅Placebo + EverolimusNovartisApproved

🔄Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3

❌Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3

🔄Lanreotide + salineIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04064346	Phase 3	Terminated	Oct 28, 2021	Aug 3, 2022	Autosomal Dominant Polycystic Kidney

Competing Products

19 competing products in Autosomal Dominant Polycystic Kidney

See all competitors

Product	Company	Stage	Hype Score
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
Placebo + Everolimus	Novartis	Approved	43
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Bosutinib + Bosutinib + Placebo	Pfizer	Phase 2	35
VX-407	Vertex Pharmaceuticals	Phase 2	42
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE	Vertex Pharmaceuticals	Phase 1	33
VX-407 + Placebo + Midazolam + VX-407	Vertex Pharmaceuticals	Phase 1	29
VX-407 + Placebo	Vertex Pharmaceuticals	Phase 1	33
Tesevatinib	Sanofi	Phase 1/2	32
Tesevatinib + Placebo	Sanofi	Phase 2	35
Venglustat + Placebo	Sanofi	Phase 2/3	30
Bardoxolone methyl oral capsule + Placebo oral capsule	Biogen	Phase 3	29
Lanreotide + saline	Ipsen	Phase 3	37
KB105	Krystal Biotech	Phase 2	28
KB105	Krystal Biotech	Phase 1/2	25
GLPG2737 + Placebo	Galapagos	Phase 2	21
QR-1123	ProQR	Phase 1/2	26